publication . Article . Other literature type . 2011

Anti-Aβ therapeutics in Alzheimer’s disease: The Need for a Paradigm Shift

Golde, Todd E.; Schneider, Lon S.; Koo, Edward H.;
Open Access
  • Published: 01 Jan 2011 Journal: Neuron, volume 69, issue 2, pages 203-213 (issn: 0896-6273, Copyright policy)
  • Publisher: Elsevier BV
Abstract
Most current Alzheimer's disease (AD) therapies in advanced phases of development target amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models suggest that anti-Aβ therapies may be highly effective if tested as agents to prevent or delay development of the disease or as therapies for asymptomatic patients with very early signs of AD pathology. However, anti-Aβ therapeutics are currently being tested in symptomatic patients where they are likely to be much less effective or ineffective. The lack of alignment between human clinical studies and preclinical studies, together with predictions about optimal trial design based on our und...
Subjects
free text keywords: Neuroscience(all), Article, General Neuroscience, Neuroscience, Early signs, Apolipoprotein e4, Alzheimer's disease, medicine.disease, medicine, Biology, Biomarker (medicine), Disease progression, Paradigm shift, Disease, Amyloid
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2011

Anti-Aβ therapeutics in Alzheimer’s disease: The Need for a Paradigm Shift

Golde, Todd E.; Schneider, Lon S.; Koo, Edward H.;